Table 4. Clinical characteristics of 135... | American Society of Hematology

Table 4.

Clinical characteristics of 135 elderly patients with acute myeloid leukemia by mutation category

	NM (N = 60)		RAS⁺ (N = 23)			FLT3⁺ (N = 43)			TP53⁺ (N = 9)			P^4-151
	No.	%	No.	%	P^4-150	No.	%	P^4-150	No.	%	P^4-150	P^4-151
Cytogenetics
Favorable	4	8	2	10	.82	3	10	.0088	0	0	.0002	< .0001
Intermediate	31	65	14	70		26	90		0	0
Unfavorable	13	27	4	20		0	0		9	100

	NM (N = 60)		RAS⁺ (N = 23)			FLT3⁺ (N = 43)			TP53⁺ (N = 9)			P^4-151
	No.	%	No.	%	P^4-150	No.	%	P^4-150	No.	%	P^4-150	P^4-151
Cytogenetics
Favorable	4	8	2	10	.82	3	10	.0088	0	0	.0002	< .0001
Intermediate	31	65	14	70		26	90		0	0
Unfavorable	13	27	4	20		0	0		9	100

	Med	Range	Med	Range	P^4-150	Med	Range	P^4-150	Med	Range	P^4-150	P^4-151
Age	68	56-84	68	56-77	.57	64	56-80	.053	69	62-88	.21	.081
Marrow blasts (%)	71	0-99	59	4-92	.035	75	19-96	.12	57	5-80	.11	.0045
WBCs (1000/μL)	18.5	0.7-216	34.2	1.5-274	.080	62.0	1.2-298	.0002	6.0	1.6-67.3	.35	.0004
Peripheral blasts (%)	30	0-95	8	0-93	.030	68	0-99	.0012	34	0-92	.62	.0002
Peripheral blasts (1000/μL)	4.1	0-95	4.1	0-119	.56	32.2	0-292	.0002	2.5	0-52.2	.41	.0003
CD34⁺ blasts (%)	70	0-95	35	0-90	.048	13	0-95	.0018	68	0-93	.99	.0092

	Med	Range	Med	Range	P^4-150	Med	Range	P^4-150	Med	Range	P^4-150	P^4-151
Age	68	56-84	68	56-77	.57	64	56-80	.053	69	62-88	.21	.081
Marrow blasts (%)	71	0-99	59	4-92	.035	75	19-96	.12	57	5-80	.11	.0045
WBCs (1000/μL)	18.5	0.7-216	34.2	1.5-274	.080	62.0	1.2-298	.0002	6.0	1.6-67.3	.35	.0004
Peripheral blasts (%)	30	0-95	8	0-93	.030	68	0-99	.0012	34	0-92	.62	.0002
Peripheral blasts (1000/μL)	4.1	0-95	4.1	0-119	.56	32.2	0-292	.0002	2.5	0-52.2	.41	.0003
CD34⁺ blasts (%)	70	0-95	35	0-90	.048	13	0-95	.0018	68	0-93	.99	.0092

	Est	95% CI	Est	95% CI	P^4-150	Est	95% CI	P^4-150	Est	95% CI	P^4-150	P^4-151
Complete response (%)	42	29-54	43	23-64	.88	58	43-73	.10	22	3-60	.28	.15
Overall survival (mo)	7	3-9	8	3-12	.37	8	6-12	.76	2	1-4	.026	.15
Relapse-free survival (mo)	8	6-19	8	3-8	.33	9	4-10	.66	—^4-153	—	.0026	.099

	Est	95% CI	Est	95% CI	P^4-150	Est	95% CI	P^4-150	Est	95% CI	P^4-150	P^4-151
Complete response (%)	42	29-54	43	23-64	.88	58	43-73	.10	22	3-60	.28	.15
Overall survival (mo)	7	3-9	8	3-12	.37	8	6-12	.76	2	1-4	.026	.15
Relapse-free survival (mo)	8	6-19	8	3-8	.33	9	4-10	.66	—^4-153	—	.0026	.099

For abbreviations, see Table 2.

Five patients with multiple mutations are omitted (2RAS⁻/FLT3⁺/TP53⁺, 2RAS⁺/FLT3⁺/TP53⁻, 1RAS⁺/FLT3⁻/TP53⁺).

F4-150

Two-tailed P value comparing each group with a single gene mutation to the patients with mutations in none of the 3 genes (NM; based on Fisher exact test for cytogenetic abnormality, CR, and RD; Wilcoxon rank sum test for continuous variables; Pearson χ² test for cytogenetic pattern; and log-rank test for OS and RFS).

F4-151

P value for overall test of heterogeneity among the four groups (based on Pearson χ² test for cytogenetic abnormality and pattern; the Kruskal-Wallis test for continuous variables; logistic regression for CR and RD; and proportional hazards regression for OS and RFS).

F4-153

Only 2 TP53⁺ patients achieved CR, which ended in relapses after 24 and 56 days.

View Large

This Feature Is Available To Subscribers Only